Back
 OJST  Vol.1 No.2 , June 2011
Maxillofacial sarcomas: a ugandan epidemiological survey
Abstract: We reviewed the case notes of 203 patients who were treated for sarcomas of the oral and maxillofacial region over a period of 5 years. There were 98 male cases (mean age 31.4 ± 12.8 years) and 105 female cases (mean age 29.3 ± 10.4). Kaposi’s sarcoma accounted for 82.8% cases, and rhabdomyosarcoma 6.9% followed by osteosarcoma and chondrosarcoma at 2.5% each. Except for Kaposi’s sarcoma, surgery in combination with radiotherapy and/or chemothe- rapy was the main stay of treatment. Survival data was not available for most of our patients.
Cite this paper: nullAdriane, K. (2011) Maxillofacial sarcomas: a ugandan epidemiological survey. Open Journal of Stomatology, 1, 50-54. doi: 10.4236/ojst.2011.12009.
References

[1]   Sturgis, M.E. and Potter, O.B. (2003) Sarcomas of the head and neck region. Current Opinion in Oncology, 15, 239-252. doi:10.1097/00001622-200305000-00011

[2]   Ahmad, Z., Qureshi, A. and Khurshid, A. (2009) The practice of histopathology in a developing country: difficulties and challenges; plus a discussion on the te- rrible disease burden we carry. Journal of Clinical Pathology, 62, 97-101. doi:10.1136/jcp.2008.061606

[3]   American Cancer Society. (2008) Cancer Facts & Figures. American Cancer Society, Atlanta.

[4]   Boutayeb, A. and Boutayeb, S. (2005) The burden of non communicable diseases in developing countries. Inter- national Journal for Equity in Health, 4, 2. http://www.equityhealthj.com/content/4/1/2 doi:10.1186/1475-9276-4-2

[5]   Dillon, P., Maurer, H., Jenkins, J., Krummel, T., Parham, D., Webber, B. and Salzberg, A. (1992) A prospective study of nonrhabdomyosarcoma soft tissue sarcomas in the pediatric age group. Journal of Pediatric Surgery, 27, 241-245. doi:10.1016/0022-3468(92)90320-7

[6]   Gurney, J.G., Swensen, A.R. and Bulterys, M. (1999) Malignant bone tumors. In: Reis, L.A.G., Smith, M.A., Gurney, J.G., et al., Eds. Cancer incidence and survival among children and adolescents: United States SEER Program, 1975-1995. National Cancer Institute SEER Program. NIH Pub., Bethesda, No. 99-4649, 99-110.

[7]   Adebayo, T.E., Ajike, O.S. and Adebola. A. (2005) Maxillo-facial sarcomas in Nigeria. Annals of African Medicine, 4, 23-30.

[8]   Chidia, L.M., Swaleh, M.S. and Godiah. M.P. (2000) Sarcomas of the head and neck at Kenyatta National Hospital. East African Medical Journal, 77, 256-259.

[9]   Yamaguchi, S., Nagasawa, H., Suzuki, T., Fujii, E., Iwaki, H., Takagi, M. and Amagasa, T. (2004) Sarcomas of the oral and maxillofacial region: a review of 32 cases in 25 years. Clinical Oral Investigations, 8, 52-55. doi:10.1007/s00784-003-0233-4

[10]   Pandey, M., Chandramohan, K., Thomas, G., Mathew, A., Sebastian, P., Somanathan, T., Abraham, K.E., Rajan, B. and Krishnan Nair, M. (2003) Soft tissue sarcoma of the head and neck region in adults. International Journal of Oral and Maxillofacial Surgery, 32, 43-48. doi:10.1054/ijom.2001.0218

[11]   Parkin, M.D., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA: Cancer Journal for Clinicians 55, 74-108. http://caonline.amcancersoc.org/cgi/content/full/55/2/74 doi:10.3322/canjclin.55.2.74

[12]   Ledergerber, B., Telenti, A. and Effer, M.(1999) Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective cohort study. British Medical Journal, 319, 23-24.

[13]   Omar, J.M., Hamza, O.J., Matee, M.I., Simon, E.N., Kikwilu, E., Moshi, M.J., Mugusi, F., Mikx, F.H., Verweij, P.E. and van der Ven, A.J. (2006) Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health, 6, 12. doi: 10.1186/1472-6831-6-12. doi:10.1186/1472-6831-6-12

[14]   Ziegler, J.L. and Katongole-Mbidde, E. (1996) Kaposi’s sarcoma in childhood:an analysis of 100 cases from Uganda and relationship to HIV infection. International Journal of Cancer, 65, 200-203.

[15]   Orem, J., Otieno, W.M. and Remick, C.S. (2004) AIDS- associated cancer in developing nations. Current Opinion in Oncology, 16, 468-476. doi:10.1097/00001622-200409000-00010

[16]   Dupin, N. and Giudice, D.P. (2008) Treatment of kaposi sarcoma in the highly active antiretroviral therapy era. Clinical Infectious Diseases, 47, 418-420. doi:10.1086/589866

[17]   Dupont, C., Vasseur, E., Beauchet, A., Aegerter, P., Berthe, H., de Truchis, P., et al. (2000) Long-term effi- cacy on Kaposi’s sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS, 14, 987-993 doi:10.1097/00002030-200005260-00010

[18]   Herzog, E.C. (2005) Overview of sarcomas in the adolescent and young adult population. Journal of Pediatric Hematology/Oncology, 27, 215-218 doi:10.1097/01.mph.0000161762.53175.e4

[19]   Chidzonga, M. and Mahomva, L. (2007) Sarcomas of the oral and maxillofacial region: A review of 88 cases in Zimbabwe. British Journal of Oral and Maxillofacial Surgery, 45, 317-318. doi:10.1016/j.bjoms.2005.11.008

[20]   van der Waal, R. and van der Waal, I. (2007) Oral non-squamous malignant tumors; diagnosis and treatment. Medicina Oral, Patología Oral y Cirugía Bucal, 12, E486-91.

 
 
Top